As Empagliflozin goes off patent, 71 copies of the key diabetes drug roll out in a month
Following the expiration of Empagliflozin's patent, the Indian pharmaceutical market has seen a surge, with 71 new brands and 17 companies introducing their versions. This influx has significantly increased sales, driven by prices that are 80-90% lower than the original. The increased affordability is expected to improve access for a wider population, with further market expansion anticipated.
RSS News
Economic times
0 thoughts on “As Empagliflozin goes off patent, 71 copies of the key diabetes drug roll out in a month”
Leave a Reply
Your email address will not be published. Required fields are marked *
